Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.

Milestones
edit

Actimis Pharmaceuticals added Fred Middleton as Director.

Posted 6/6/09 at 7:18am
Actimis Pharmaceuticals added Peter C. M. McWilliams as Chairman and Acting CEO.

Posted 6/6/09 at 7:18am
Actimis Pharmaceuticals added Taro Inaba as Director.

Posted 6/6/09 at 7:18am
Actimis Pharmaceuticals added Kevin B. Bacon as Founder, CSO and Head of Research & Development .

Posted 6/6/09 at 7:18am
Actimis Pharmaceuticals received $6M in Series A funding. (4/28/05)

Posted 8/28/10 at 5:32am via actimis.com
Actimis Pharmaceuticals received $9.6M in Venture Round funding. (6/6/08)

Posted 6/6/09 at 7:18am
Actimis Pharmaceuticals was acquired by Boehringer Ingelheim for $515M. (6/17/08)

Posted 9/14/09 at 6:02pm via boehringer-ingelheim.com